Antifungals in systemic neonatal candidiasis

Drugs

Volumn 64, Issue 9, 2004, Pages 949-968

  Frattarelli, Daniel A C ^a,d   Reed, Michael D ^b   Giacoia, George P ^c   Aranda, Jacob V ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CANDICIDIN; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN B DERIVATIVE; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; FLUOROPYRIMIDINE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MEPARTRICIN; MICAFUNGIN; MICONAZOLE; NATAMYCIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TETRACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANEMIA; BONE MARROW SUPPRESSION; CANDIDIASIS; CARDIODEPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; ELECTROLYTE DISTURBANCE; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEPATITIS; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEWBORN; PHARMACOGENETICS; POLYURIA; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; VASOCONSTRICTION; VOMITING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FLUCONAZOLE; FLUCYTOSINE; FUNGAL PROTEINS; HUMANS; INFANT, NEWBORN; PEPTIDES; PEPTIDES, CYCLIC;

EID: 2342650755     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464090-00003     Document Type: Review

References (128)

1. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics 1984; 73: 144-52
2. Baley JE, Silverman A. Systemic candidiasis: cutaneous manifestations in low birth-weight infants. Pediatrics 1988; 82: 211-5
3. Faix RG, Kovarik SM, Shaw TR, et al. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989; 83 (1): 101-7
4. Johnson DE, Thompson TR, Green TP, et al. Systemic candidiasis in very low-birth-weight infants (less than 1500 grams). Pediatrics 1984 Feb; 73 (2): 138-43
5. Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome®). Infection 1998; 26: 11-5
6. Edwards MS. Fungal and protozoal infections. In: Fanaroff AA, Martin RJ, editors. Neonatal-perinatal medicine: diseases of the fetus and Infant. St Louis (MO): Mosby-Year Book Inc., 2002: 745-51
7. Weese-Mayer DE, Fondriest DW, Brouillette RT, et al. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987; 6: 190-6
8. Rowen JL, Tate JM. Management of neonatal candidiasis: Neonatal Candidiasis Study Group. Pediatr Infect Dis J 1998; 17 (11): 1007-11
9. Stoll BJ, Gordon T, Korones SB, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996 Jul; 129 (1): 72-80
10. Leibovitz E. Neonatal candidosis: clinical picture, management controversies and consensus, and new therapeutic options. J Antimicrob Chemother 2002; 49 Suppl. 1: 69-73
11. Saiman L, Ludington E, Dawson JD, et al. The National Epidemiology of Mycoses Study Group. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20 (12): 1119-24
12. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000; 19 (4): 319-24
13. Ng PC. Systemic fungal infections in neonates. Arch Dis Child 1994; 71: F130-5
14. Evdoridou J, Roilides E, Bibashi E, et al. Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 1997; 25 (2): 112-6
15. Anderson DC, Pickering LK, Feigin RD. Leukocyte function in normal and infected neonates. J Pediatr 1974; 85 (3): 420-5
16. Shigeoka AO, Charette RP, Wyman ML, et al. Defective oxidative metabolic responses of neutrophils from stressed neonates. J Pediatr 1981; 98 (3): 392-8
17. Cairo MS. Neonatal neutrophil host defense: prospects for immunologic enhancement during neonatal sepsis. Am J Dis Child 1989; 143 (1): 40-6
18. Baley JE, Kliegman RM, Boxerbaum B, et al. Fungal colonization in the very low birth weight infant. Pediatrics 1986; 78: 225-32
19. Welbel SF, McNeil MM, Kuykendall RJ, et al. Candida parapsilosis bloodstream infections in neonatal intensive care unit patients: epidemiologic and laboratory confirmation of a common source outbreak. Pediatr Infect Dis J 1996; 15 (11): 998-1002
20. Donovick R, Gold W, Pagano JF, et al. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I: in vitro studies. Antibiotic Annu 1955-1956; 3: 579-86
21. Bennett JE. Antifungal agents. In: Hardman GE, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1295-312
22. Raasch RH, Hopfer RL. Antifungal agents. In: Munson PL, editor. Principles of pharmacology: basic concepts and clinical applications, revised reprint. New York: Chapman and Hall, 1996: 1401-11
23. Collette N, van der Auwera P, Pascual Lopez A, et al. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B deoxycholate. Antimicrob Agents Chemother 1989; 33 (3): 362-8
24. Atkinson AJ, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13: 271-6
25. Starke JR, Mason Jr EO, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987; 155 (4): 766-74
26. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116 (5): 791-7
27. Inselmann G, Volkmann A, Heidemann HT. Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cytochrome P-450 in rats. Antimicrob Agents Chemother 2000; 44 (1): 131-3
28. Botsch S, Gautier JC, Beaune P, et al. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993; 43 (1): 120-6
29. AmBisome. In: Physician's desk reference. 54th ed. Montvale (NJ): Medical Economics Co. Inc., 2000: 1090-2
30. Adler-Moore J, Proffitt RJ. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar liposomal preparation of amphotericin B. J Liposome Res 1993; 3: 429-50
31. Abelcet. In: Physician's desk reference. 54th ed. Montvale (NJ): Medical Economics Co. Inc., 2000: 1653-5
32. Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 2000; 20 (11): 1335-55
33. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol 1998; 38 (7): 583-92
34. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27 (3): 603-18
35. Juliano RL, Grant CW, Barber KR, et al. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987; 31 (1): 1-11
36. Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998; 42 (4): 767-71
37. Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001; 17 (3): 161-9
38. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12 (4): 501-17
39. Vandevelde AG, Mauceri AA, Johnson III JE. 5-Fluorocytosine in the treatment of mycotic infections. Ann Intern Med 1972; 77 (1): 43-51
40. Hill HR, Mitchell TG, Matsen JM, et al. Recovery from disseminated candidiasis in a premature neonate. Pediatrics 1974; 53 (5): 748-52
41. Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145 (Pt 10): 2701-13
42. Sanglard D. Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 2002; 20 (9): 462-9
43. Samaranayake YH, Samaranayake LP. Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen. J Med Microbiol 1994; 41 (5): 295-310
44. Pelletier R, Loranger L, Marcotte H, et al. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 2002; 51 (6): 479-83
45. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia: NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39 (1): 40-4
46. Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997; 41 (6): 1392-5
47. Marr B, Gross S, Cunningham C, et al. Candidal sepsis and meningitis in a very-low-birth-weight infant successfully treated with fluconazole and flucytosine. Clin Infect Dis 1994; 19 (4): 795-6
48. Wyble LE, Gal P, Ransom JL, et al. Fluconazole use and pharmacokinetics in three premature neonates. Pharmacotherapy 1991; 11: 269-70
49. Wong SF, Leung MP, Chan MY. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. Clin Ther 1997; 19 (5): 1039-47
50. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82 (3): 511-6
51. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996; 42 (4): 465-70
52. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49 (4): 420-5
53. Wiest DB, Fowler SL, Garner SS, et al. Fluconazole in neonatal disseminated candidiasis [letter]. Arch Dis Child 1991; 66 (8): 1002
54. Krzeska I, Yeats RA, Pfaff G. Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs Exp Clin Res 1993; 19 (6): 267-71
55. Saxén H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993; 54 (3): 269-77
56. Wenzl TG, Schefels J, Hornchen H, et al. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr 1998; 157 (8): 661-2
57. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001; 55: 633-8
58. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500
59. Neely MN, Ghannoum MA. The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 897-914
60. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose phamacokinetics of LY 30336, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898-905
61. Stone J, Holland S, Li S, et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin [abstract no. A-14]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago
62. Nelly M, Blumer J. Caspofungin pharmacokinetics in two pediatric liver transplant patients. Clin Ther Res 2003; 64: 127-36
63. Mukai T, Ohkuma T, Nakahara K, et al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects [abstract no. A-30]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001 Dec 16-19; Chicago
64. Driessen M, Ellis J, Cooper P, et al. Fluconazole vs amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996; 15: 1107-12
65. Faix RG. Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. J Pediatr 1984; 105: 616-22
66. Smego R, Perfect J. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984; 6: 791-801
67. Hall JE, Cox F, Karlson K, et al. Amphotericin B dosage for disseminated candidiasis in premature infants. J Perinatol 1987; 7 (3): 194-8
68. Loke HL, Verber I, Szymonowicz W, et al. Systemic candidiasis and pneumonia in preterm infants. Aust Paediatr J 1988; 24 (2): 138-42
69. Butler K, Rench M, Baker C. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9: 51-6
70. Leibovitz E, Iuster-Reicher A, Amitai M, et al. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis 1992; 14: 485-91
71. Glick C, Graves G, Feldman S. Neonatal fungemia and amphotericin B. South Med J 1993; 86: 1368-71
72. Donowitz L, Hendley J. Short-course amphotericin B therapy for candidemia in pediatric patients. Pediatrics 1995; 95: 888-91
73. Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31: 458-63
74. Zenker PN, Rosenberg EM, Van Dyke RB, et al. Successful medical treatment of presumed Candida endocarditis in critically ill infants. J Pediatr 1991; 119 (3): 472-7
75. Sanchez PJ, Siegel JD, Fishbein J. Candida endocarditis: successful medical management in three preterm infants and review of the literature. Pediatr Infect Dis J 1991 Mar; 10 (3): 239-43
76. Chesney PJ, Justman RA, Bogdanowicz WM, et al. Candida meningitis in newborn infants: a review and report of combined amphotericin b-flucytosine therapy. Johns Hopkins Med J 1978; 142 (5): 155-60
77. Lilien LD, Ramamurthy RS, Pildes RS. Candida albicans meningitis in a premature neonate successfully treated with 5-fluorocytosine and amphotericin B: a case report and review of the literature. Pediatrics 1978; 61 (1): 57-61
78. Dennis D, Miller MJ, Peterson CG. Candida septicemia. Surg Gynecol Obstet 1969; 119: 520-30
79. Kozinn PJ. Candida meningitis successfully treated with amphotericin B. N Engl J Med 1963; 268: 881-4
80. Klein JD, Yamachi T, Horlick SP. Neonatal candidiasis, meningitis, and arthritis: observations and a review of the literature. J Pediatr 1972; 81 (1): 31-4
81. Adler S, Randall J, Plotkin SA. Candidal osteomyelitis and arthritis in a neonate. Am J Dis Child 1972; 123 (6): 595-6
82. Mahboubi S, Kaufmann HJ, Schut L. Two instances of inflammatory aqueductal occlusion in prematures after neonatal candidal septicemia. Clin Pediatr (Phila) 1976; 15 (7): 651-3
83. Ingomar CJ, Terslev E. Candida albicans meningitis hos en nyft: tilfaelde kompliceret med hydrocephalus. Ugeskr Laeger 1964; 126: 1110-2
84. Nezelof C, Sarrut S. Infections mortelles à candida chez le nouveau-né et le nourisson: six observations anatomohistologiques. Ann Pediatr 1957; 33: 2949-58
85. Bayer AS, Edwards Jr JE, Seidel JS, et al. Candida meningitis: report of seven cases and review of the English literature. Medicine (Baltimore) 1976; 55 (6): 477-86
86. Michelson PE, Rupp R, Efthimiadis B. Endogenous candida endophthalmitis leading to bilateral corneal perforation. Am J Ophthalmol 1975; 80 (5): 800-3
87. Pittard III WB, Thullen JD, Fanaroff AA. Neonatal septic arthritis. J Pediatr 1976; 88 (4 Pt 1): 621-4
88. Svirsky-Fein S, Langer L, Milbauer B, et al. Neonatal osteomyelitis caused by candida tropicalis: report of two cases and review of the literature. J Bone Joint Surg Am 1979; 61 (3): 455-9
89. Oleinik EM, Della-Latta P, Rinaldi MG, et al. Candida lusitaniae osteomyelitis in a premature infant. Am J Perinatol 1993; 10 (4): 313-5
90. Ward RM, Sattler FR, Dalton Jr AS. Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 1983; 72 (2): 234-8
91. Pruitt AW, Achord JL, Fales FW, et al. Glucose-galactose malabsorption complicated by monilial arthritis. Pediatrics 1969; 43 (1): 106-10
92. Omene JA, Odita JC, Okolo AA. Neonatal osteomyelitis in Nigerian infants. Pediatr Radiol 1984; 14 (5): 318-22
93. Pfaller MA, Bale M, Buschelman B, et al. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol 1995; 33 (5): 1104-7
94. Huang YC, Kao HT, Lin TY, et al. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. Am J Perinatol 2001; 18 (3): 141-6
95. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. Wayne (PA): NCCLS, 1997
96. van den Anker JN, van Popele NM, Sauer PJ. Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother 1995; 39 (7): 1391-7
97. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis: Infectious Diseases Society of America. Clin Infect Dis 2000 Apr, 30 (4): 662-78
98. Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001; 84 (2): F131-3
99. López Sastre JB, Coto Cotallo GD, Fernández Colomer B; Grupo de Hospitales Castrillo. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol. 2003; 20 (3): 153-63
100. da Silva LP, Amaral JM, Ferreira NC. Which is the most appropriate dosage of liposomal Amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low birth weight? Pediatrics 1993; 91 (6): 1217-8
101. al Arishi H, Frayha HH, Kalloghlian A, et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 1997; 14 (9): 573-6
102. al Arishi H, Frayha HH, Kalloghlian A, et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 1998; 15 (11): 643-8
103. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998; 17 (2): 146-8
104. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000; 28 (4): 223-6
105. Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46 (3): 834-40
106. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21 (9): 1107-14
107. Rao HKM, Myers GJ. Candida meningitis in the newborn. South Med J 1979; 72 (11): 1468-71
108. Bennett JE. Flucytosine: diagnosis and treatment, drugs five years later. Ann Intern Med 1997; 86: 319-22
109. Isacson M, Faber NJ, Herishano Y, et al. Use of 5-flurocytosine in systemic candidiasis in infancy. Arch Dis Child 1972; 47: 954-9
110. Holt RJ, Newman RL. The treatment of urinary candidiasis with the oral antifungal drugs 5-fluorocytosine and 'clotrimazole'. Dev Med Child Neurol 1972; 14 (27): 70-9
111. Smith H, Congdon P. Neonatal systemic candidiasis. Arch Dis Child 1985; 60: 365-9
112. Fasano C, O'Keeffe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994; 13 (4): 351-4
113. Bilgen H, Ozek E, Korten V, et al. Treatment of systemic neonatal candidiasis with fluconazole [letter]. Infection 1995; 23 (6): 394
114. Narang A, Agrawal P, Chakraborti A, et al. Fluconazole in the management of neonatal systemic candidiasis. Indian Pediatr 1996; 33 (10): 823-6
115. Merchant RH, Sanghvi KP, Sridhar N, et al. Nursery outbreak of neonatal fungal arthritis treated with fluconazole. J Trop Pediatr 1997; 43 (2): 106-8
116. Wainer S, Cooper PA, Gouws H, et al. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997; 16 (8): 763-7
117. Driessen M, Ellis JB, Muwazi F, et al. The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 1997; 17 (3): 263-71
118. Huttova M, Hartmanova I, Kralinsky K, et al. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998; 17 (11): 1012-5
119. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345 (23): 1660-6
120. Tollins JP, Raij L. Adverse effects of amphotericin B administration on renal hemodynamics in the rat: neurohumoral mechanisms and influence of calcium channel blockade. J Pharmacol Exp Ther 1998; 245: 594-9
121. Steinmetz PR, Hustead RF. Amphotericin B toxicity of epithelial cells. In: Porter GA, editor. Nephrotoxic mechanisms of drugs and environmental toxins. New York (NY): Kluwer Academic/Plenum Publishers, 1982: 95-8
122. Ramos KS, Chacon E, Acosta D. Toxic responses of the heart and vascular systems. In: Klassen CD, editor. Casarett and Doul's toxicology: the basic science of poisons. 5th ed. New York: McGraw-Hill, 1996: 498-501
123. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 1994; 28 Suppl. 1: 17-24
124. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics 1984; 73: 153-7
125. Turner RB, Donowitz LG, Hendley JO. Consequences of candidemia for pediatric patients. Am J Dis Child 1985; 139: 178-80
126. Kingo A, Smith J, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J 1997; 16: 1002-3
127. Lackner H, Schwinger W, Urban C, et al. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight Pediatrics 1992; 89 (6 Pt 2): 1259-61
128. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83 (2): 236-42